Osteoporosis in Men: What has Changed?
- First Online:
- 221 Downloads
Osteoporosis in men is finally receiving some attention; it has been realized that men are more likely to die after hip fracture. Methods for screening men for osteoporosis include dual energy x-ray absorptiometry and use of fracture risk calculators such as FRAX (World Health Organization) and the Garvan nomogram. Evaluation of men will often identify secondary causes of osteoporosis as well as multiple risk factors. Alendronate, risedronate, zoledronic acid, and teriparatide are US Food and Drug Administration (FDA)—approved therapy for men. Men on androgen deprivation therapy (ADT) are at high risk for bone loss and fracture, and all the bisphosphonates have been shown to increase bone density. The new antiresorptive drug, denosumab, although FDA-approved only for postmenopausal women, has been shown in a study of men on ADT to increase bone density in spine, hip, and forearm and decrease vertebral fractures on x-ray. Thus, there is great progress in osteoporosis in men, and recognition of its importance is increasing.
KeywordsOsteoporosis Men Fracture Screening Dual-energy x-ray absorptiometry Testosterone Androgen deprivation therapy Bisphosphonates Teriparatide Denosumab
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.Adler RA: Osteoporosis in men. In Osteoporosis—Pathophysiology and Clinical Management 2nd Edition. Edited by Adler RA, New York, Humana/Springer; 2010:545–557.Google Scholar
- 6.• Ryan CS, Petkov VI, Adler RA. Osteoporosis in men: the value of laboratory testing. Osteoporos Int 2010, published on line October 9. This recent publication provides information on how to evaluate men with osteoporosis. Google Scholar
- 12.Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010, published on line June 16.Google Scholar
- 20.• Chaganti RK, Parimi N, Lang T, et al. Bone mineral density and prevalent osteoarthritis of the hip in older men for the Osteoporosis fractures in men (MrOS) study group. Osteoporos Int 2010, 21:1307–1316. Although it has been known that arthritic changes in the spine affect bone density, this study shows that the hip BMD can be affected by arthritis as well. CrossRefPubMedGoogle Scholar
- 22.Nelson HD, Haney EM, Dana T, Bougatsos C, Chou R. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2010, published on line July 20.Google Scholar
- 26.ISCD official positions 2007. www.iscd.org. Accessed October 25, 2010.
- 31.• Sandhu SK, Nguyen ND, Center JR, et al. Prognosis of fracture: evaluation of predictive accuracy of the FRAX™ algorithm and the Garvan nomogram. Osteoporos Int 2009, published on line July 29. This is an interesting validation study in which the Garvan nomogram outperformed FRAX in men. Google Scholar
- 33.• Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older while men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res 2010, 25:1506–1511. This study demonstrates just how many men would be eligible for treatment based on the NOF guidelines. Google Scholar
- 35.Van der Klift, De Laet C, McCloskey EV, et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam study. J Bone Miner Res 2004, 19:1172–1180.Google Scholar
- 38.Johnson DA, Williams MI, Petkov VI, Adler RA, Zoledronic acid treatment of osteoporosis: effects in men. Endocr Pract 2010, published on line May 24.Google Scholar
- 39.Orwoll E, Miller P, Adachi J, et al. Efficacy and safety of once-yearly i.v. infusion of zoledronic acid 5 mg versus once-weekly 70 mg of oral alendronate in the treatment of male osteoporposis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010, 25:2239–2250.CrossRefPubMedGoogle Scholar
- 41.• Greenspan SL, Nelson JB, Trump DL, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 2008, 26:4426–4434. In men on ADT, stopping bisphosphonate therapy has consequences. CrossRefPubMedGoogle Scholar
- 42.Taxel P, Dowsett R, Richter L, et al. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Internat 2010, published on line April 30.Google Scholar